Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179,948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.
Cheng B, Li C, Li J, Gong L, Liang P, Chen Y, Zhan S, Xiong S, Zhong R, Liang H, Feng Y, Wang R, Wang H, Zheng H, Liu J, Zhou C, Shao W, Qiu Y, Sun J, Xie Z, Liang Z, Yang C, Cai X, Su C, Wang W, He J, Liang W. Cheng B, et al. Among authors: chen y. Signal Transduct Target Ther. 2024 Apr 19;9(1):93. doi: 10.1038/s41392-024-01799-z. Signal Transduct Target Ther. 2024. PMID: 38637495 Free PMC article. Clinical Trial.
C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Wei Y, Xu J, Huang X, Xie S, Lin P, Wang C, Guo Y, Zou S, Zhao Z, Wen W, Song Y, Bao Z, Zhang L, Liu W, Kong W, Wang W, He B, Zhang S, Zhou C, Chen Y, Yu Z. Wei Y, et al. Among authors: chen y. J Thorac Dis. 2023 Apr 28;15(4):1892-1900. doi: 10.21037/jtd-23-240. Epub 2023 Apr 17. J Thorac Dis. 2023. PMID: 37197527 Free PMC article.
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
Zhao Y, He Y, Wang W, Cai Q, Ge F, Chen Z, Zheng J, Zhang Y, Deng H, Chen Y, Lao S, Liang H, Liang W, He J. Zhao Y, et al. Among authors: chen z, chen y. Lancet Oncol. 2024 Oct;25(10):1347-1356. doi: 10.1016/S1470-2045(24)00379-6. Epub 2024 Aug 16. Lancet Oncol. 2024. PMID: 39159630
Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report.
Blechter B, Hsiung CA, Wang X, Zhang H, Seow WJ, Shi J, Chatterjee N, Kim HN, Wong MP, Hong YC, Wong JYY, Dai J, Hosgood HD, Wang Z, Chang IS, Choi J, Wang J, Song M, Hu W, Zheng W, Kim JH, Zhou B, Albanes D, Shin MH, Chung LP, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Vermeulen RCH, Bassig BA, Chang J, Man Ho JC, Ji BT, Kubo M, Daigo Y, Momozawa Y, Kamatani Y, Honda T, Kunitoh H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Su J, Kim YH, Oh IJ, Fun Lee VH, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Lin HC, Seow A, Park JY, Kweon SS, Chen CJ, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Chen TY, Burdett L, Yeager M, Hutchinson A, Berndt SI, Wu W, Wang J, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Chen CH, Xu J, Guan P, Tan W, Wang CL, Loon Sihoe AD, Chen Y, Choi YY, Kim JS, Yoon HI, Cai Q, Park IK, Xu P, He Q, Chen CY, Wu J, Lim WY, Chen KC, Chan JKC, Li J, Chen H, Yu CJ, Jin L, Fraumeni JF Jr, Liu J, Landi MT, Yamaji T, Yang Y, Hicks B, Wyatt K, Li S… See abstract for full author list ➔ Blechter B, et al. Among authors: chen k, chen ky, chen ym, chen ty, chen ch, chen kc, chen cy, chen cj, chen h, chen y. J Thorac Oncol. 2024 Nov 22:S1556-0864(24)02482-1. doi: 10.1016/j.jtho.2024.11.019. Online ahead of print. J Thorac Oncol. 2024. PMID: 39581378
179,948 results
You have reached the last available page of results. Please see the User Guide for more information.